Private: Gallery Post #1

29

Jun2021
This morning, June 29th, 2021, Health Canada announced an additional 6-month delay in implementation of the Patented Medicines Regulations and Final PMPRB Guidelines.  The changes will now come into force on January 1, 2022. The reasons cited by Health Canada for the delay are the ongoing COVID-19 pandemic and need ... Read More

14

Jun2021
Information regarding the PMPRB guidelines and the upcoming webinar can be found here. Registration is required to attend the webinar and can be completed here. Online Filing Tool & Transition Measures for Grandfathered and Gap MedicinesDate: Tuesday June 15th, 2021Time: 1:30-3:30pm For inquiries on ... Read More

20

May2021
ISPOR 2021 runs between May 17-20 with the theme of HEOR: Evolving for Tomorrow's Challenges. During the conference, PDCI Market Access will be presenting a poster titled: Identification of Gaps and Opportunities for Provincial Reimbursement of Oncology Companion Diagnostics in Canada on May 18th 2021 from 11:30:00 AM ... Read More

06

May2021
The PMPRB is developing a Guideline Monitoring and Evaluation Plan (GMEP) that will analyze trends in the pharmaceutical market before and after the implementation of the new framework to assess whether it is working as intended, and to inform the need for any future adjustments. The PMPRB ... Read More

19

Apr2021
The PMPRB has announced it has revisited it’s March 17, 2021 decision regarding timelines for compliance for Grandfathered and Gap medicines.  The Board has reset the maximum list price (MLP) compliance timeline for these drugs to 2 PMPRB reporting periods, rather than their amended 1 reporting period timeline. MLP compliance for ... Read More

14

Apr2021
BACKGROUNDThe National Advisory Committee on Immunization (NACI) provides the Public Health Agency of Canada (PHAC) with ongoing and timely medical, scientific, and public health advice relating to immunization.Traditionally, NACI reviewed safety, efficacy, immunogenicity, effectiveness and burden of illness in making recommendations for vaccine programs. PHAC has now expanded ... Read More

29

Mar2021
CADTH’s Pharmaceutical Reviews Updates are used to communicate new CADTH reimbursement review process updates to the public. PDCI has outlined below the key highlights from the most recent update. For more information, please consult the CADTH website.... Read More

29

Mar2021
The PMPRB has published the long awaited 2019 Annual Report. The following are some of the high-level takeaways: Sales of patented medicines in Canada reached $17.2 billion in 2019, a moderate increase of 3.5% from the ... Read More

24

Mar2021
This is a reminder that PDCI is inviting all stakeholders to share their input for public awareness and information. PDCI strives to support timely transparency around public policy consultations and invites organizations and individuals to share their submissions here so ideas ... Read More

18

Mar2021
On January 15, 2021, PMPRB invited stakeholders to comment on two key amendments to the final guidelines that were originally to come into affect for January 1, 2021 but were delayed to July 1, 2021. PMPRB received 48 submissions in response to the definition of Gap Medicines and ... Read More